Roche (VTX:ROG) received a CHF 226 target price from stock analysts at Kepler Capital Markets in a research note issued on Wednesday. The firm presently has a “neutral” rating on the healthcare company’s stock. Kepler Capital Markets’ price target points to a potential downside of 3.09% from the stock’s previous close.
A number of other analysts have also weighed in on ROG. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the company a “buy” rating in a research note on Thursday, September 21st. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a research note on Thursday, January 11th. UBS Group restated a “neutral” rating on shares of Roche in a research note on Monday. Jefferies Group set a CHF 300 price objective on shares of Roche and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Deutsche Bank set a CHF 264 price objective on shares of Roche and gave the company a “neutral” rating in a research note on Monday. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of CHF 258.95.
Roche (VTX:ROG) opened at CHF 233.20 on Wednesday. The stock has a market cap of $201,090.00 and a PE ratio of 20.73. Roche has a 12 month low of CHF 226.10 and a 12 month high of CHF 273.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.